FDA approves Welireg with pembrolizumab for renal cell carcinoma
medicalxpress - The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma in adults with a clear ce…
AI Summary: The FDA cleared Welireg (belzutifan) in combination with pembrolizumab for adjuvant treatment of renal cell carcinoma at high risk of recurrence after surgery. The approval expands belzutifan’s indications, offering a new post‑nephrectomy option intended to lower recurrence risk and reflecting regulators’ willingness to endorse targeted therapy combinations in kidney cancer.
Related Stories
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 15 days
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 5 wks
Datroway secures regulatory approvals in breast cancer across US and EU / 28 days
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 5 wks
FDA grants early access to experimental pancreatic cancer drug / 6 wks
FDA approves relacorilant plus nab‑paclitaxel for resistant ovarian cancers / 2 months
FDA flags misleading cancer drug claims tied to biotech billionaire / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Oncology, FDA, Cancer Research, Mergers and Acquisitions and look for the RSS link.
StackHealth Time Machine